resTORbio, Inc. (NASDAQ: TORC) today announced the initiation of a Phase 1b/2a trial of RTB101, its orally administered, small molecule ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE